Takeda Announces Divestment of Multilab to Novamed
Takeda Announces Divestment of Multilab to Novamed
Osaka, Japan, April 5, 2018 ―Takeda Pharmaceutical Company Limited (TSE: 4502) today announced it has signed an agreement with Novamed Fabricação de Produtos Farmacêuticos Ltda., (Novamed), to sell/divest all shares, and all its assets in, Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. to Novamed.
Takeda is committed to continuing to help meet the unmet needs of patients in Brazil and to maintaining its ‘best-in-class’ position in its core therapeutic areas, including Gastroenterology and Oncology. Taking into careful consideration the future development of Multilab's business, Takeda is confident that Novamed, part of the NC Group which owns some of the largest pharmaceutical companies in Brazil, will develop the future business of Multilab by leveraging the synergies of both companies.
1. Overview of Multilab
|
(1) |
Company name |
Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. | |||||
|
(2) |
Headquarters |
São Jerônimo, Rio Grande do Sul, Brazil | |||||
|
(3) |
Name of representative |
Renata Rodrigues Campos | |||||
|
(4) |
Business description |
Research, development, manufacturing and sales of pharmaceutical products | |||||
|
(5) |
Capital |
BRL 688 million | |||||
|
(6) |
Date of establishment |
1988 | |||||
|
(7) |
Major shareholders and percentage of shares held |
Takeda Pharma A/S |
100% | ||||
|
(8) |
Relationships between Takeda and Multilab |
Capital relationship |
Takeda Pharmaceutical Company Limited holds all the outstanding shares of Takeda Pharma A/S, which holds all of the outstanding shares of Multilab. | ||||
|
Personnel relationship |
Not Applicable | ||||||
|
Transactional relationship |
Not Applicable | ||||||
|
(9) |
Operating result and financial conditions for the last three years | ||||||
|
Accounting period |
Fiscal year ended March 2015 |
Fiscal year ended March 2016 |
Fiscal year ended March 2017 | ||||
|
Net assets (million yen) |
16,800 |
10,612 |
10,276 | ||||
|
Total assets (million yen) |
21,197 |
19,175 |
20,916 | ||||
|
Net assets per share (yen) |
31.99 |
20.21 |
17.58 | ||||
|
Sales (million yen) |
7,473 |
5,701 |
5,390 | ||||
|
Operating income |
-1,831 |
-2,057 |
-2,292 | ||||
|
Net income (million yen) |
-1,917 |
-3,499 |
-3,664 | ||||
|
Earnings per share (yen) |
-3.65 |
-6.66 |
-6.42 | ||||
2. Overview of Novamed
Company name : Novamed Fabricação de Produtos Farmacêuticos Ltda.
Location : Brazil
Relationships between Takeda:
|
Capital relationship |
Not Applicable |
|
Personnel relationship |
Not Applicable |
|
Transactional relationship |
Not Applicable |
|
Whether Novamed constitutes a related party |
Not Applicable |
3. Change in Ownership Ratio of Shares through the Divestment
|
(1) |
Number of shares held prior to the divestment |
688,217,037 shares (Takeda Pharma A/S: 688,217,037 shares) (Number of votes：688,217,037) (% of total votes：100%) |
(2) |
Number of shares to be divested |
688,217,037 shares (Takeda Pharma A/S: 688,217,037 shares) (Number of votes：688,217,037） |
|
(3) |
Number of shares held after the divestment |
0 shares (Number of votes：0) (% of total votes：0.00%) |
The divestment price is undisclosed in accordance with an agreement with Novamed, and was assessed rationally based on discussions between Takeda and Novamed.
4. Schedule of the Divestment
|
(1) |
Date of governance meeting resolution |
March 20, 2018 |
|
(2) |
Date of conclusion of the agreement |
March 22, 2018 |
|
(3) |
Date of transfer of shares |
June, 2018 (TBC) |
5. Outlook
The impact of the divestment on Takeda's consolidated results for FY2017 is minimal. Takeda’s financial forecast for FY2018, including the impact of this divestment, will be announced in May 2018.
Media Contacts:
Media outside Japan
Vince Docherty
[email protected]
+65 8332 4233
Japanese Media
Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095